Johannes F. van Agthoven

Johannes F. van Agthoven

Auto-generated profile, based on publicly available information

Johannes F. van Agthoven

Nephrology Division, Mass General Brigham, Harvard Medical School, Boston, MA, United States

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
DWDonghai Wen
Donghai Wen
QZQian Zhang
Qian Zhang
JAJohannes van Agthoven
Johannes van Agthoven
AWAstrid Weins
Astrid Weins
IRIvy A. Rosales
Ivy A. Rosales
EREugene P. Rhee
Eugene P. Rhee
Key Points: Testican-2 reduced adriamycin-induced podocyte injury in vitro and in vivo . Testican-2 interacted with vitronectin and reduced vitronectin-mediated integrin α V β 3 activation in vitro . Exogenous testican-2 circulated to the kidney, bound vitronectin, and conferred podocyte protection, even when endogenous testican-2 was absent. Background: Testican-2 is a podocyte-derived glycoprotein encoded by SPOCK2 . Circulating levels of testican-2 are associated with less glomerulosclerosis and better kidney prognosis, but its biologic function in the podocyte is unknown. Methods: We studied the protective effect of testican-2 on immortalized cultured human podocytes and in mice treated with adriamycin. We used immunoprecipitation mass spectrometry to identify binding partners of testican-2 and biolayer interferometry to characterize these protein–protein interactions. Using global and podocyte-specific Spock2 knockout mice, we assessed the effect of testican-2 deficiency in models of podocyte injury and also tested whether exogenous testican-2 confers podocyte protection in testican-2–deficient mice. Finally, we analyzed testican-2 expression in human kidney biopsy samples. Results: Testican-2 reduced adriamycin-induced podocyte injury in cultured human podocytes and mice. Vitronectin was a strong binding partner for testican-2, and testican-2 inhibited the interaction between vitronectin and integrin α V β 3, an effector of podocyte injury. Consistent with this, testican-2 administration reduced activation of integrin β 3 in injured podocytes. Furthermore, Spock2 deficiency increased susceptibility to podocyte injury due to adriamycin- and streptozotocin-induced diabetes, as determined by albuminuria, foot process effacement, nephrin expression, and Wilms' tumor 1-positive podocyte number. Importantly, exogenous testican-2 circulated to the kidney, bound to vitronectin, reduced vitronectin-integrin β 3 interaction, and reduced podocyte injury in Spock2 -deficient mice. Finally, glomerular testican-2 expression was reduced in human focal segmental glomerulosclerosis and diabetic kidney disease, but not tubulointerstitial nephropathy. Conclusions: Testican-2 modulated the podocyte's interaction with its extracellular matrix and had a functional role in kidney protection.

9 May 2026 in Matrix Biology
Verified
Journal Article
Closed access
YWYan Wang
Yan Wang
JAJohannes F. van Agthoven
Johannes F. van Agthoven
EREugene P. Rhee
Eugene P. Rhee
DWDonghai Wen
Donghai Wen